Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.
Location: South Africa, North West, Atlanta
Employees: 1-10
Total raised: $196M
Founded date: 2018
Investors 10
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.11.2021 | Series B | $75M | - |
| 13.04.2021 | Series B | $96M | - |
| 27.11.2018 | Series A | $25M | - |
Mentions in press and media 21
| Date | Title | Description |
| 04.11.2021 | Google Cloud goes deep into financial services with $1 billion CME deal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. I didn’t see this coming. Paid Content Why empathic leadership is critical to business success Fr... |
| 04.11.2021 | Google Cloud goes deep into financial services with $1 billion CME deal | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. I didn’t see this coming. Paid Content 4 ways CEOs can build a successful cloud strategy From PwC... |
| 03.11.2021 | Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV | MENDHAM, NJ – November 03, 2021 — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of ... |
| 03.11.2021 | Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV | MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the su... |
| 03.11.2021 | Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV | - |
| 03.11.2021 | Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV | MENDHAM, N.J. /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of a $75... |
| 03.11.2021 | Antios, months after series B, raises a further $75M to fuel pursuit of hepatitis B cure | Antios Therapeutics is going full throttle in pursuit of a curative hepatitis B therapy, raising $75 million just months after its previous round to accelerate phase 2b development of its lead prospect. The drug candidate, ATI-2173, is a tw... |
| 03.11.2021 | Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV | Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of a $75 million Series B-1 financing... |
| 03.11.2021 | Antios, months after series B, raises a further $75M to fuel pursuit of hepatitis B cure | Antios Therapeutics is going full throttle in pursuit of a curative hepatitis B therapy, raising $75 million just months after its previous round to accelerate phase 2b development of its lead prospect. Antios is still fairly early in the p... |
| 13.04.2021 | Antios Therapeutics Raises $96M in a Series B | ATLANTA, GA, Antios Therapeutics announced the successful completion of a $96 million Series B financing led by Soleus Capital. >> Click here for more funding data on Antios Therapeutics >> To export Antios Therapeutics fund... |
Show more